menu
    • menu

    Company profile for Sentynl Therapeutics

    NEW Drugs in Dev: 3
    Granules India Limited has high volume world-class facilities for APIs, PFIs, & FDFs, serving customers in over 80 countries.

    Virtual Booth

    Contact Supplier

    Lupin Manufacturing Solutions – delivering high-quality APIs & end-to-end CDMO services for faster, cost-effective drug development.

    Virtual Booth

    Contact Supplier

    Mission CDMO team brings reliability, resourcefulness, & responsiveness in executing your development project.

    Virtual Booth

    Contact Supplier

    Egis is a Hungarian generic pharma company with 110 years history. Our activities incorporate all areas of the pharma value chain.

    Virtual Booth

    Contact Supplier

    AbbVie CDMO has been working with global companies to develop, manufacture & scale biopharmaceutical products.

    Virtual Booth

    Contact Supplier

    pharmacompass-2-2026-02-09

    Virtual Booth

    Contact Supplier

    EVENTS

    DIGITAL CONTENT

    DEVELOPMENTS

    INSPECTIONS & REGISTRATIONS

    PharmaCompass

    Only Regulatory Products (API/FDF), Drugs in Developments and News are Updated on this Virtual Booth

    Update your Virtual Booth on PharmaCompass, ask us

    About

    Sentynl Therapeutics is a biopharmaceutical company headquartered in the United States, dedicated to providing innovative therapies for patients suffering from rare diseases. Acquired by the Zydus Group in 2017, Sentynl benefits from the support and resources of a global healthcare conglomerate. At Sentynl, we prioritize ethical conduct and adhere strictly to all applicable laws, regulations, and industry standards. Our commit...
    Sentynl Therapeutics is a biopharmaceutical company headquartered in the United States, dedicated to providing innovative therapies for patients suffering from rare diseases. Acquired by the Zydus Group in 2017, Sentynl benefits from the support and resources of a global healthcare conglomerate. At Sentynl, we prioritize ethical conduct and adhere strictly to all applicable laws, regulations, and industry standards. Our commitment to upholding the highest ethical standards underscores our dedication to improving patient outcomes and advancing healthcare.

    List your booth number for exhibitions, ask us

    CONTACT DETAILS

    Click the arrow to open the dropdown
    Contact SupplierContact
    Google MapGoogle Map
    Full View ScreenFull View Screen
    Sentynl TherapeuticsUnited_States_of_America Flag
    Country
    Country
    U.S.A
    Address
    Address
    Solana Beach, CA 92075
    Telephone
    Telephone
    Client Email
    Email
    enquiries@pharmacompass.com
    Client Website
    Website
    https://sentynl.com/
    Linkedin
    Linkedin
    https://www.linkedin.com/company/sentynl-therapeutics-inc-/
    youtube
    YouTube
    Twitter
    Twitter

    Upload your Marketing & Sales content on your company Virtual Booth, click HERE.

    Events

    Webinars & Exhibitions

    Request a meetingRequest a meeting
    Full Screen ViewFull Screen View
    Default Event

    euroPLX 90 Lisbon

    Not Confirmed

    envelop Contact Supplier

    euroPLX 90 Lisbon

    Post an Enquiry

    Meeting

    Digital content

    Create Content with PharmaCompass, ask us

    NEWS #PharmaBuzz

    read-more
    read-more
    Fortress Unit Cyprium Sells Rare Pediatric PRV For $205M
    Fortress Unit Cyprium Sells Rare Pediatric PRV For $205M

    23 Feb 2026

    // GLOBENEWSWIRE

    https://www.globenewswire.com/news-release/2026/02/23/3242632/28889/en/Fortress-Biotech-s-Subsidiary-Cyprium-Therapeutics-Enters-into-Agreement-to-Sell-Rare-Pediatric-Disease-Priority-Review-Voucher-for-205-Million.html

    GLOBENEWSWIRE
    23 Feb 2026
    Share Share
    Sentynl Therapeutics Inc. Announces FDA Approval of ZYCUBO
    Sentynl Therapeutics Inc. Announces FDA Approval of ZYCUBO

    12 Jan 2026

    // PRESS RELEASE

    https://sentynl.com/news/zycubo-fda-approval/

    PRESS RELEASE
    12 Jan 2026
    Share Share
    Fortress Biotech and Cyprium Announce FDA Approve ZYCUBO
    Fortress Biotech and Cyprium Announce FDA Approve ZYCUBO

    12 Jan 2026

    // FDA

    https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=211241

    FDA
    12 Jan 2026
    Share Share
    Sentynl Therapeutics Announces FDA Acceptance Of CUTX-101 NDA
    Sentynl Therapeutics Announces FDA Acceptance Of CUTX-101 NDA

    15 Dec 2025

    // PR NEWSWIRE

    https://www.prnewswire.com/news-releases/sentynl-therapeutics-announces-fda-acceptance-of-cutx-101-nda-resubmission-302642214.html

    PR NEWSWIRE
    15 Dec 2025
    Share Share
    Sentynl Selects Mytomorrows To Lead Managed Access Program
    Sentynl Selects Mytomorrows To Lead Managed Access Program

    10 Dec 2025

    // PR NEWSWIRE

    https://www.prnewswire.com/news-releases/sentynl-selects-mytomorrows-to-lead-managed-access-program-302637819.html

    PR NEWSWIRE
    10 Dec 2025
    Share Share
    Fortress Bio, Cyprium Therapeutics Update NDA For CUTX-101
    Fortress Bio, Cyprium Therapeutics Update NDA For CUTX-101

    01 Oct 2025

    // GLOBENEWSWIRE

    https://www.globenewswire.com/news-release/2025/10/01/3159486/28889/en/Fortress-Biotech-and-Cyprium-Therapeutics-Announce-an-Update-on-the-NDA-for-CUTX-101.html

    GLOBENEWSWIRE
    01 Oct 2025
    Share Share

    Inspections and registrations

    Upload your audits for free, ask us

    ABOUT THIS PAGE

    Ask Us for Pharmaceutical Supplier and Partner
    Ask Us, Find A Supplier / Partner
    No Commissions, No Strings Attached, Get Connected for FREE

    What are you looking for?

    How can we help you?

    The request can't be empty

    Please read our Privacy Policy carefully

    You must agree to the privacy policy

    The name can't be empty
    The company can't be empty.
    The email can't be empty Please enter a valid email.
    The mobile can't be empty
    • Privacy policy
    • Terms and conditions
    • Disclaimers
    • LinkedIn
    • Product listings are provided for informational purposes only. We do not supply or sell any products. Any products that may be covered by patent(s) are supplied solely for uses permitted under Section 107A of the Indian Patents Act and not for commercial sale.

    Market Place

    Market Place

    PharmaCompass

    Home

    Market Place

    Menu

    Post Enquiry

    Post Enquiry

    Market Place

    Market Place

    Search